The future of patent-based injunctions in doubt in India after explosive Delhi High Court ruling
Bayer has failed to block an Indian generic rival from exporting an erectile dysfunction drug in a case that one observer says breaks new ground in considering how to weigh public interest issues relating to the grant or not of patent-based…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.